{"count": 2, "results": [{"_id": "18343246", "pmid": 18343246, "title": "Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial.", "journal": "Clin Ther", "authors": ["Barrios V", "Escobar C", "Tomás JP", "Calderon A", "Echarri R"], "date": "2008-01-01T00:00:00Z", "doi": "10.1016/j.clinthera.2008.01.007", "meta_date_publication": "2008 Jan", "meta_volume": "30", "meta_issue": "1", "meta_pages": "98-107", "score": 50046.086, "text_hl": "OBJECTIVE: The CARDHIAC (CARduran en pacientes Diabeticos con HIpertensi'on Arterial no Controlada) trial examined the effects of @CHEMICAL_Doxazosin @CHEMICAL_MESH:D017292 @@@doxazosin@@@ gastrointestinal therapeutic system (GITS) and @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ on 3 separate measures of target-organ @<m>DISEASE_Lead_Poisoning_Nervous_System</m> @DISEASE_MESH:D020263 @@@damage@@@--left ventricular mass index (LVMI), carotid intima media thickness (IMT), and urinary albumin excretion (UAE)--in @SPECIES_9606 @@@patients@@@ with @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes mellitus@@@ and @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@. ", "citations": {"NLM": "Barrios V, Escobar C, Tomás JP, Calderon A, Echarri R. Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial. Clin Ther. 2008 Jan;30(1):98-107. PMID: 18343246", "BibTeX": "@article{18343246, title={Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial.}, author={Barrios V and Escobar C and Tomás JP and Calderon A and Echarri R}, journal={Clin Ther}, volume={30}, number={1}, pages={98-107}}"}}, {"_id": "10764416", "pmid": 10764416, "title": "beta-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction.", "journal": "Circ Res", "authors": ["Senzaki H", "Paolocci N", "Gluzband YA", "Lindsey ML", "Janicki JS", "Crow MT", "Kass DA"], "date": "2000-04-14T00:00:00Z", "doi": "10.1161/01.res.86.7.807", "meta_date_publication": "2000 Apr 14", "meta_volume": "86", "meta_issue": "7", "meta_pages": "807-15", "score": 50044.062, "text_hl": "@<m>DISEASE_Lead_Poisoning_Nervous_System</m> @DISEASE_MESH:D020263 @@@Myocellular damage@@@ with fibroblast/neutrophil infiltration from Ang II+48hP was also inhibited by high- but not low-dose @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@, whereas collagen content was not elevated with either dose. ", "citations": {"NLM": "Senzaki H, Paolocci N, Gluzband YA, Lindsey ML, Janicki JS, Crow MT, Kass DA. beta-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction. Circ Res. 2000 Apr 14;86(7):807-15. PMID: 10764416", "BibTeX": "@article{10764416, title={beta-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction.}, author={Senzaki H and Paolocci N and Gluzband YA and Lindsey ML and Janicki JS and Crow MT and Kass DA}, journal={Circ Res}, volume={86}, number={7}, pages={807-15}}"}}]}